EOM Pharmaceuticals Holdings, Inc.
IMUC · OTC
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.29 | -1.59 | 0.59 | 0.09 |
| FCF Yield | -0.74% | 0.00% | 0.00% | -0.00% |
| EV / EBITDA | -303.43 | -137.66 | 0.00 | -37.76 |
| Quality | ||||
| ROIC | 1,428.04% | 3,366.64% | 0.00% | -212.43% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.48 | – | 0.70 | 0.29 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 34.93% |
| Safety | ||||
| Net Debt / EBITDA | -9.05 | -3.52 | 0.00 | -2.44 |
| Interest Coverage | 0.00 | 0.00 | -20.22 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |